Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

Published:2002-07-01 Issue:1 Volume:20 Page:73-78
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:European Respiratory Journal

Author:

Buhl R.,Soler M.,Matz J.,Townley R.,O'Brien J.,Noga O.,Champain K.,Fox H.,Thirlwell J.,Della Cioppa G.

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract;Meditsinskiy sovet = Medical Council;2023-11-16

2. Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study;Drugs;2023-07-12

3. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis;The Journal of Allergy and Clinical Immunology: In Practice;2023-05

4. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study;The Lancet Respiratory Medicine;2023-05

5. The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis;Frontiers in Immunology;2023-04-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP